Harvard Bioscience Aktie
WKN: 578107 / ISIN: US4169061052
11.04.2025 04:09:14
|
Harvard Bioscience CFO Jennifer Cote Resigns; Names Mark Frost Interim CFO
(RTTNews) - Harvard Bioscience Inc. (HBIO) announced the resignation of Jennifer Cote, the Company's Chief Financial Officer and Treasurer. Cotes resignation will be effective upon the filing of the Company's Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025.
In addition, the company announced that it appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Cotes resignation.
Frost has over 30 years of financial and executive-level management experience from both private and public companies. He has served as a consultant to the Company since January 2025. Frost previously served as the Chief Financial Officer of Fathom. Prior to joining Fathom, Frost was Chief Financial Officer for Argon Medical Devices, a medical devices company planning to go public in Hong Kong.
Prior to Argon, Frost also served as the Chief Financial Officer for three public Healthcare companies including Analogic, AngioDynamics and AMRI. Frost began his career with General Electric, where he held a variety of finance roles over the course of fourteen years.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Harvard Bioscience Inc.mehr Nachrichten
23.04.25 |
NASDAQ Composite Index-Titel Harvard Bioscience-Aktie: So viel Verlust hätte ein Harvard Bioscience-Investment von vor 3 Jahren eingefahren (finanzen.at) | |
22.04.25 |
Gute Stimmung in New York: NASDAQ Composite zum Ende des Dienstagshandels stärker (finanzen.at) | |
17.04.25 |
NASDAQ-Handel: NASDAQ Composite beginnt Donnerstagshandel in der Gewinnzone (finanzen.at) | |
16.04.25 |
NASDAQ Composite Index-Wert Harvard Bioscience-Aktie: So viel Verlust hätte eine Investition in Harvard Bioscience von vor einem Jahr bedeutet (finanzen.at) | |
16.04.25 |
Schwacher Handel: NASDAQ Composite schwächelt zum Handelsstart (finanzen.at) | |
10.04.25 |
Verluste in New York: NASDAQ Composite beendet den Handel weit im Minus (finanzen.at) | |
10.04.25 |
Zurückhaltung in New York: NASDAQ Composite bricht nachmittags ein (finanzen.at) | |
09.04.25 |
Optimismus in New York: NASDAQ Composite verbucht zum Ende des Mittwochshandels deutliche Zuschläge (finanzen.at) |
Analysen zu Harvard Bioscience Inc.mehr Analysen
Aktien in diesem Artikel
Harvard Bioscience Inc. | 0,32 | -3,07% |
|